Yep, the patients are the most serious refractory patients, so it's not an unexpected outcome that a subject unfortunately passes during the trial. I don't think it would have hurt sentiment to disclose it though. It doesn't relate to dose limiting toxicity (one of the primary safety concerns), so I would've liked to have the additional disclosure.
The combination trial with Onyx and their Kyprolis is a result of the strong response from refractory patients who had previously been resistant to first line of care drugs.
Fingers crossed
PAB Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held
